FILE:JNJ/JNJ-8K-20060217171851.txt.gz
EVENTS:	Completion of Acquisition or Disposition of Assets
TEXT:
ITEM: Completion of Acquisition or Disposition of Assets
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
 o
   
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 o
   
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 o
   
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 o
   
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Item 2.01
 
Completion of Acquisition or Disposition of Assets
On February 17, 2006, Johnson & Johnson issued a press release announcing that it completed its acquisition of Animas Corporation in accordance with the Agreement and Plan of Merger dated as of December 16, 2005, by and among Johnson & Johnson, Emerald Merger Sub, Inc. and Animas Corporation. As a result of the acquisition each issued and outstanding share of Animas Corporation common stock was converted into the right to receive $24.50.
 A copy of the press release is attached hereto as exhibit 99.1 and is incorporated by reference. The foregoing description of the press release is qualified in its entirety by reference to the full text of the press release.
   
   
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 17, 2006
 
 
 
  
Exhibit

                          & #160;  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Exhibit 99.1
Johnson & Johnson
Media Contact:  
   
   
Marc Monseau
       732-524-1130
   
   
   
   
Investor Contacts: 
   
  
Louise Mehrotra                    
Stan Panasewicz
 732-524-6491
    
    
   
  
   
   
732-524-2524
 
 
FOR IMMEDIATE RELEASE
NEW BRUNSWICK, NJ
, February 17, 2006 -- Johnson & Johnson (NYSE: JNJ) today announced the completion of its previously announced acquisition of Animas Corporation, an insulin delivery company.
Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 200 Johnson & Johnson operating companies employ approximately 115,600 men and women in 57 countries and sell products throughout the world.


